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Introduction: The treatment with antitumor necrosis factor agents has often been associated with the induction
of autoantibodies (antinuclear antibodies, anti-double stranded DNA antibodies and antiphospholipid antibodies).
The clinical significance of these antibodies remains unclear, but they may predispose to antiphospholipid
syndrome with thromboembolic complications. The association of etanercept with thromboembolic events has not
been reported previously in the literature.
Case presentation: We describe the cases of three patients with rheumatoid arthritis, psoriatic arthritis and
seronegative inflammatory arthritis who were treated with etanercept. They developed deep vein thrombosis and/
or pulmonary embolism one to three years after the initiation of etanercept therapy. All three patients had a
prolonged activated partial thromboplastin time with a positive lupus anticoagulant that persisted even after 12
weeks.
Conclusion: Although the clinical significance of antiphospholipid antibodies during treatment with antitumor
necrosis factor agents remains unclear, they may predispose patients to develop antiphospholipid syndrome when
associated with prolonged activated partial thromboplastin time, lupus anticoagulant positivity, or the presence of
anti-b2 glycoprotein I. Clinicians must keep this in mind during therapy with antitumor necrosis factor agents in
order to prevent, detect and treat potential consequences such as deep vein thrombosis and pulmonary
embolism.
Introduction
Etanercept (Enbrel; Immunex; Thousand Oaks, Califor-
nia) is a dimeric recombinant DNA protein composed
of two naturally occurring soluble human tumor necro-
sis factor (TNF) receptors linked to the Fc portion of
IgG1. TNF plays an important role in inflammatory pro-
cesses and binds into two different types of receptors,
wherein one becomes embedded in white blood cells
and is responsible for the immune response and the
other becomes a soluble TNF receptor used to deacti-
vate TNF and blunt immune response. Etanercept
mimics the inhibitory effects of naturally occurring solu-
ble TNF receptors. The only difference is that etaner-
cept is a fusion protein rather than a simple TNF
receptor and has a greatly extended half-life in the
bloodstream, and therefore has a more profound and
long-lasting biologic effect than a naturally occurring
soluble TNF receptor.
Pulmonary embolism (PE) has been previously
described in the literature with infliximab (monoclonal
antibody against TNF) [1]. In this case report, we
describe the cases of three patients who developed deep
vein thrombosis (DVT) leading to PE during etanercept
therapy. All patients were seen at one medical center
over a 3-year period.
Case presentation
We report the cases of three patients with rheumatoid
arthritis, psoriatic arthritis and seronegative inflamma-
tory arthritis who were treated with etanercept.
Our first patient is a 60-year-old Hispanic man with a
four-year history of rheumatoid arthritis (RA). He was
treated previously with a combination of various dis-
ease-modifying antirheumatic drugs and corticosteroids.
Etanercept therapy, which proved successful in treating
his RA, was started for a flare up three years prior to
his presentation with right calf swelling and acute onset
dyspnea. A spiral computed tomography (CT) scan * Correspondence: makol@msu.edu
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pulmonary arteries. A Doppler scan showed right
femoral DVT. He denied any history of smoking, recent
immobilization, surgery or travel, or any personal or
family history of clotting disorders. He had never been
on heparin therapy. His activated partial thromboplastin
time (aPTT) was 48 seconds. He tested positive for
lupus anticoagulant (LAC) and anticardiolipin antibody
(aCL), which persisted for 12 weeks along with pro-
longed aPTT.
Our second patient is a 56-year-old Caucasian man
with psoriatic arthritis who had been treated for three
years with once-a-week doses of methotrexate and a daily
high dose of prednisone. He had a flare up on that regi-
men, so etanercept therapy was started. He developed
progressively increasing aches in his left calf after one
and a half years of therapy. A Doppler scan revealed tibial
DVT. He did not smoke and had no previous prolonged
immobilization, travel, trauma, or surgery. He had
neither a personal nor family history of clotting disorders
and he had never been on heparin therapy. His aPTT was
found to be 51 seconds and workup was positive for LAC
and anti-b2 glycoprotein I. All three remained positive
when he returned for follow-up after three months.
Our third patient is a 46-year-old Caucasian woman
with seronegative inflammatory arthritis that was poorly
controlled by methotrexate for four years. She was
started on etanercept and developed left lower extremity
swelling and dyspnea after one year of therapy. A scan
Doppler showed left tibial DVT. A CT scan of her chest
showed left lower lobe PE. This was her first episode of
DVT and she denied any recent prolonged immobiliza-
tion, trauma, surgery or travel, but she had a matrilineal
family history of blood clots. The results of a procoagu-
lant workup, including antiphospholipid antibody syn-
drome (APS) screen, prior to etanercept initiation were
negative. She had never been on heparin therapy. Her
aPTT was 44 seconds and a workup revealed that she
was positive for LAC and aCL. These symptoms
remained positive at three months follow-up.
Discussion
Anti-TNF-alpha agents are a powerful addition to our
armamentarium in arthritides therapy. Their role in the
pathogenesis of thromboembolic events is complex. The
production of autoantibodies (antinuclear antigen, anti-
dsDNA and antiphospholipid) during treatment is well
documented and there are several mechanisms proposed
[2,3], which include the following: 1) TNF-alpha inhibi-
tion that causes B-cell activation and autoantibody pro-
duction through the upregulation of interleukin-10 [3,4];
2) an increase in Th2 activity [5], and 3) an increase in
bacterial infections [6] that leads to the production of
antibodies through molecular mimicry.
Antiphospholipids (aPLs) (aCLs, anti-beta2 glycopro-
t e i nIo rL A C )a r ef o u n di n2 %t o6 %o fh e a l t h yi n d i v i -
duals and have been associated with recurrent
thromboembolism and fetal loss with APS. However,
the induction of antiphospholipids is often considered as
a nonspecific marker of activated immune system [7,8]
such as cardiac thrombosis (associated with aCLs), and
they may disappear over time. Some studies have shown
the correlation between treatment with anti-TNF-alpha
agents, the appearance of aCLs, and clinical outcomes in
terms of disease activity and adverse effects including
thromboembolic events [2].
In our patients, the following measurements were
obtained before the anticoagulant therapy was started to
treat the DVT and/or PE: procoagulant work-up includ-
ing aPTT with a reference range of 18 to 28 seconds;
aPLs with IgM and IgG aCLs measured by enzyme-
linked immunosorbent assay (ELISA), levels > 20 MPL/
GPL considered positive; anti-beta2 glycoprotein I levels
measured by ELISA, > 20 SMU/GMU considered posi-
tive; LAC detected using dilute Russell’sv i p e rv e n o m
assay and confirmed with 1:1 dilution of plasma from
patients with normal plasma to rule out factor deficien-
cies and confirm phospholipid dependency; protein C;
protein S; antithrombin III, Factor V Leiden; homocys-
teine; and prothrombin gene mutation (Table 1). All
three patients had prolonged aPTT and tested positive
for LAC. The aPLs persisted to be positive at three
months follow-up and hence consistent with the diagno-
sis of APS.
One patient had a family history of blood clots but the
results of a procoagulant work-up prior to the initiation
of etanercept treatment were normal. In addition, these
patients were not on any medications that are associated
with hypercoagulablity. Although a causal relationship
cannot be established, the events had a temporal asso-
ciation with etanercept therapy and hence could be cor-
related. PE has been described with procainamide-
induced lupus and positive aCLs [9]. Also,
Table 1 Procoagulant work-up (Post-clinical event but
prior to the initiation of anticoagulant therapy)
Patient 1 Patient 2 Patient 3
Antinuclear antigen N N N
Anticardiolipin antibodies P N P
Lupus anticoagulant P P P
anti-b2 glycoprotein I N P N
Antithrombin III N N N
Homocysteine N N L
Factor 5 Leiden N N N
Prothrombin mutation N N N
Proteins C and S N N N
N, normal or negative; P, positive; L, low.
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described with the treatment of infliximab [1].
The data associating anti-TNF agents with hypercoa-
gulablity are still in the preliminary stages, but these
cases suggest that etanercept-induced LAC positivity
may be a contributing factor to venous thromboembo-
lism. The limitation of this clinical experience, however,
is its involvement of only three patients and the unavail-
ability of baseline data on aPLs prior to the initiation of
etanercept therapy in two of the three patients. In addi-
tion, this clinical observation is insufficient to explain if
there is, indeed, an increased risk of thromboembolic
events associated with etanercept in these patients as
compared with the general population.
Conclusion
Our observations have a potentially strong impact
because anti-TNF agents are widely used in a variety of
conditions across several aspects of medical practice.
Although the role of aPLs in the development of throm-
boembolism in our patients is uncertain, the potential
complications of anti-TNF therapy should be remem-
bered in order to prevent, detect, and manage thrombo-
tic events.
Consent
Written informed consent was obtained from the
patients for publication of these case reports and any
accompanying images. Copies of the written consent are
available for review by the Editor-in-Chief of this
journal.
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